BiomX Q1 net loss $6.4M; cash $30.3M; positive Part 1 BX004 data; PIPE closed

BiomX Inc.

2023-Q1 EPS reported $0.20

Net loss $6.4M vs $8.2M YoY; R&D expense $4.6M; cash $30.3M as of March 31, 2023.
Positive Phase 1b/2a Part 1 BX004 results: >90% reduction in P. aeruginosa CFU; no safety events; Part 2 data expected Q3 2023.
Completed $7.5M PIPE with OrbiMed and CF Foundation; second closing in May 2023.
Jason M. Marks and Michael E. Dambach appointed to Board of Directors.
Cash runway sufficient into Q3 2024.

item 2.02 item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Michael E. Dambach

Class II Director

PHGE · BiomX Inc.

Effective: 2023-05-11
Filed: May 15, 2023, 7:59 PM ET

On May 11, 2023, the Board of Directors of the Company (the “Board”), pursuant to a recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed each of Jason M. Marks and Michael E. Dambach to serve as Class II Directors of the Company, with terms expiring at the Company’s 2025 annual meeting of stockholders, in order to fill two of the three existing vacancies on the Board.

Appointed

Jason M. Marks

Class II Director

PHGE · BiomX Inc.

Effective: 2023-05-11
Filed: May 15, 2023, 7:59 PM ET

On May 11, 2023, the Board of Directors of the Company (the “Board”), pursuant to a recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed each of Jason M. Marks and Michael E. Dambach to serve as Class II Directors of the Company, with terms expiring at the Company’s 2025 annual meeting of stockholders, in order to fill two of the three existing vacancies on the Board.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael E. Dambach was appointed as Class II Director at BiomX Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On May 11, 2023, the Board of Directors of the Company (the “Board”), pursuant to a recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed each of Jason M. Marks and Michael E. Dambach to serve as Class II Directors of the Company, with terms expiring at the Company’s 2025 annual meeting of stockholders, in order to fill two of the three existing vacancies on the Board.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Jason M. Marks was appointed as Class II Director at BiomX Inc..

Action: appointed
Role: Class II Director

Exact text from the filing

On May 11, 2023, the Board of Directors of the Company (the “Board”), pursuant to a recommendation of the Nominating and Corporate Governance Committee of the Board (the “Nominating Committee”), appointed each of Jason M. Marks and Michael E. Dambach to serve as Class II Directors of the Company, with terms expiring at the Company’s 2025 annual meeting of stockholders, in order to fill two of the three existing vacancies on the Board.

View on SEC.gov

BiomX Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-039291

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.